Buying and selling at the same time

Halma (LSE:HLMA) has long grown by acquiring small, specialised technology companies, but the first half of its 2027 financial year stood out even by its own standards. The group said it had completed six acquisitions worth £515 million, a record, while also selling three businesses. How the safety, environmental and healthcare technology group is reshaping its portfolio, and what its trading update says about performance, is explored here.

The business

Halma plc is a group of companies that develop technologies for safety, environmental monitoring and healthcare applications, organised into Safety, Environmental and Analysis, and Healthcare sectors. The company states that it is listed on the London Stock Exchange and is a constituent of the FTSE 100 index. Its model relies on largely autonomous operating companies, supported by central Capital allocation and a steady flow of acquisitions. Marc Ronchetti is group chief executive and Carole Cran is chief financial officer.

The trading update

On 24 September 2026, Halma issued a trading update for the first half of its financial year, the six months to 30 September 2026. The company said it had completed six acquisitions in the year to date, investing £515 million. The largest were Dreampath Diagnostics for €279 million (£238 million) and Pyxis, a Houston-based water quality business, for up to US$200 million (£148 million) with earn-out, alongside Näslund Medical for US$45 million and itemedical for €23 million. At the same time, three disposals raised about £83 million net, including NovoBone for US$56 million.

The update also stated that Halma expected low double-digit organic constant currency Revenue growth for the full year, with photonics contributing about five percentage points. It set new guidance for an adjusted EBIT Margin of 23.5% to 24% for the 2027 financial year. Ronchetti referred to "broad-based growth against a backdrop of continued economic, geopolitical and market uncertainty". The company expected sterling strength to reduce revenue by about £8 million and profit by about £2 million through currency translation.

Financial context

The results for the year to 31 March 2026, published on 11 June 2026, provide the base. Revenue rose 15% to £2,582.3 million, with organic growth of 16%, including about eight percentage points from photonics. Adjusted EBIT increased 22% to £594.5 million, a margin of 23.0%, and statutory profit before tax rose 27% to £520.7 million. Adjusted Earnings Per Share grew 21% to 114.05p, and the total Dividend rose 7% to 24.74p, which the company described as its 47th consecutive year of dividend increases of 5% or more.

In that year Halma completed five acquisitions for £447 million. Net Debt rose to 1.16 times adjusted EBITDA, within its operating range of up to 2.0 times. Adjusted return on total invested capital was 16.2%, and cash conversion was 93%. These figures indicate that the group has capacity to fund further deals, though the latest spending is likely to push Leverage higher.

Risks and points to watch

Large acquisitions bring integration risk and can dilute returns if growth disappoints, and Dreampath alone accounts for close to half of the year-to-date Acquisition spend. Photonics has contributed a significant share of organic growth, which may not be sustained at the same pace. Currency movements, geopolitical uncertainty and healthcare regulation could affect results. Post-deal leverage is currently unreported. Half-year results will provide fuller detail on margins and leverage after the acquisitions.

Conclusion

Halma is reshaping its portfolio by investing a record £515 million in acquisitions, led by Dreampath and Pyxis, while selling businesses such as NovoBone, which recycles part of that capital back into the group. Its trading update indicates continued organic growth and higher margin expectations. Execution on integration will determine whether the larger acquisition programme delivers the returns the company targets.